Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med. 2020;45(6):1631–43.

CAS  PubMed  PubMed Central  Google Scholar 

Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan, ST . COVID-19: A global challenge with old history, epidemiology and progress so far. Molecules. 2021;26:39. https://doi.org/10.3390/molecules26010039. Accessed 25 Mar 2024

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. https://doi.org/10.1038/s41564-020-0695-z. Accessed 25 Mar 2024.

Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): Stat Pearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.

Efrati S, Catalogna M, Abu Hamed R, Hadanny A, Bar-Chaim A, Benveniste-Levkovitz P, et al. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients. Sci Rep. 2021;11(1):13780.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Network Open. 2021;4(1):e2035057-e.

Article  Google Scholar 

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad KH. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1–9.

Article  CAS  PubMed  Google Scholar 

Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aronson JK. Coronaviruses–a general introduction. Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford. 2020.  https://www.cebm.net/covid-19/coronaviruses-a-general-introduction/. Accessed 25 Mar 2024.

Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med. 2021;27(3):401–10. https://doi.org/10.1038/s41591-021-01282-0. Accessed 25 Mar 2024.

Article  CAS  PubMed  Google Scholar 

Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;170:1–25.

Article  CAS  PubMed  Google Scholar 

Wang J, Peng Y, Xu H, Cui Z, Williams RO. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. 2020;21(6):225.

Article  PubMed  Google Scholar 

Resistance is … complex. Nat Ecol Evol. 2018;2(3):405-.

Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J. 1990;272(2):281–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21(7):1189–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romano CM, Chebabo A, Levi JE. Past, present, and future of COVID-19: a review. Braz J Med Biol Res. 2020;53(9):e10475.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2021;11:631736-.

Article  PubMed  PubMed Central  Google Scholar 

Akil A, Eliza IJ, Hisham M, Hussain H, Morshed F, Sakib N, et al. The Past, Present, and Future of COVID-19: A Data-Driven Perspective. arXiv preprint arXiv:200805531. 2020.

Ganesh B, Rajakumar T, Malathi M, Manikandan N, Nagaraj J, Santhakumar A, et al. Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. Clin Epidemiol Global Health. 2021;10:100694.

Article  CAS  Google Scholar 

Tyrrell D, Bynoe M. Cultivation of a novel type of common-cold virus in organ cultures. BMJ. 1965;1(5448):1467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loke MF, Hanafi A. Molecular Mechanisms Responsible for Drug Resistance. In: Ranganathan S, Gribskov M, Nakai K, Schönbach C, editors. Encyclopedia of Bioinformatics and Computational Biology. Oxford: Academic Press; 2019. p. 926–31.

Chapter  Google Scholar 

Kumar M, Kuroda K, Dhangar K, Mazumder P, Sonne C, Rinklebe J, et al. Potential Emergence of Antiviral-Resistant Pandemic Viruses via Environmental Drug Exposure of Animal Reservoirs. Environ Sci Technol. 2020;54(14):8503–5.

Article  CAS  PubMed  Google Scholar 

Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021;57(4):106324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Callaway E. The coronavirus is mutating-does it matter? Nature. 2020;585(7824):174–7.

Article  CAS  PubMed  Google Scholar 

Ragonnet-Cronin M, Nutalai R, Huo J, Dijokaite-Guraliuc A, Das R, Tuekprakhon A, et al. Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2. bioRxiv. 2022;2022–07.

Awasthi P. First-gen Covid vaccines would be ineffective in a year due to constant virus mutation: Experts Mumbai: BusinessLine; 2021 [Available from: https://www.thehindubusinessline.com/news/first-gen-covid-vaccines-would-be-ineffective-in-a-year-due-to-constant-virus-mutation-experts/article34205143.ece. Accessed 25 Mar 2024.

FDA Approved Drug Products: VEKLURY (remdesivir) injection. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatmentcovid-19. Accessed 25 Mar 2024

Padhi AK, Shukla R, Saudagar P, Tripathi T. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance. Iscience. 2021;24(1):101992.

Article  CAS  PubMed  Google Scholar 

Szemiel AM, Merits A, Orton RJ, MacLean O, Wickenhagen A, Lieber G, et al. In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2. BioRxiv. 2021.

Kumar D, Singh S, Yadav D, et al. Prediction of remdesivir resistance in COVID-19 illness: Need for development of clinical laboratory test. Indian J Clin Biochem. 2021;36:498–499. https://doi.org/10.1007/s12291-021-00987-w. Accessed 25 Mar 2024.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282. Accessed 25 Mar 2024.

Article  PubMed  Google Scholar 

Stower H. Lopinavir–ritonavir in severe COVID-19. Nature Medicine. 2020;26(4):465-.

PubMed  Google Scholar 

Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagul Inflamm Cross-talking Virus Res. 2020;286:198070.

CAS  Google Scholar 

Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18(14):1965–6.

Article  PubMed  Google Scholar 

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, et al. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 2012;67(4):995–1000.

Article  CAS  PubMed  Google Scholar 

Nijhuis M, Wensing AMJ, Bierman WFW, de Jong D, Kagan R, Fun A, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis. 2009;200(5):698–709.

Article  CAS  PubMed  Google Scholar 

Sood S, Bhatia GK, Seth P, Kumar P, Kaur J, Gupta V, et al. Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone. Curr Pharmacol Reports. 2021;1–6.

Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. https://doi.org/10.1038/s41598-021-90551-6. Accessed 25 Mar 2024.

Article  CAS  PubMed  PubMed Central